Patents Assigned to Biogen, Inc.
-
Publication number: 20030198649Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.Type: ApplicationFiled: May 29, 2003Publication date: October 23, 2003Applicant: Biogen, Inc.Inventor: Kenneth Murray
-
Publication number: 20030190307Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contact with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.Type: ApplicationFiled: March 24, 2003Publication date: October 9, 2003Applicant: Biogen, Inc.Inventors: Mary D. DiBiase, Wen-Li Chung, Mark Staples, Eric Scharin
-
Patent number: 6630503Abstract: A cell adhesion inhibitor of the general formula: R3—L—L′—R1 is disclosed. An inhibitor of the present invention interacts with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. Also disclosed are methods for preparing and using such a cell adhesion inhibitor, as well as pharmaceutical compositions containing the same.Type: GrantFiled: August 14, 2000Date of Patent: October 7, 2003Assignee: Biogen, Inc.Inventors: Daniel Scott, Wen-Cherng Lee, Russell C. Petter, Mark Cornebise
-
Patent number: 6630512Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.Type: GrantFiled: October 23, 2001Date of Patent: October 7, 2003Assignee: Biogen, Inc.Inventors: Steven P. Adams, Ko-Chung Lin, Wen-Cherng Lee, Alfredo C. Castro, Craig N. Zimmerman, Charles E. Hammond, Yu-Sheng Liao, Julio Hernan Cuervo, Juswinder Singh
-
Publication number: 20030185819Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.Type: ApplicationFiled: May 2, 2003Publication date: October 2, 2003Applicant: Biogen, Inc., a Massachusetts corporationInventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
-
Patent number: 6627202Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV cote antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.Type: GrantFiled: June 4, 2001Date of Patent: September 30, 2003Assignee: Biogen, Inc.Inventor: Kenneth Murray
-
Patent number: 6624152Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.Type: GrantFiled: August 22, 2001Date of Patent: September 23, 2003Assignee: Biogen, Inc.Inventors: Steven P. Adams, Ko-Chung Lin, Wen-Cherng Lee, Alfredo C. Castro, Craig N. Zimmerman, Charles E. Hammond, Yu-Sheng Liao
-
Patent number: 6605601Abstract: Compounds of Formula I and II are disclosed as antagonists of subtype A1 adenosine receptors. These compounds are useful for treatment of various diseases and disorders, including systemic hypertension, renal failure, diabetes, asthma, an edematous condition, congestive heart failure, and renal dysfunction.Type: GrantFiled: November 30, 2001Date of Patent: August 12, 2003Assignee: Biogen, Inc.Inventors: Ko-Chung Lin, Chi Vu
-
Publication number: 20030148382Abstract: An isolated polynucleotide encoding a novel immunoglobulin superfamily member named PanCAM (also named GP354) is provided. PanCAM has a predicted single membrane spanning domain and five immunoglobulin (Ig) domains in the extracellular portion of the protein. The protein structure and tissue distribution of PanCAM indicate that it plays a role in cell-cell recognition, binding, signaling and adhesion events in the pancreas (especially the beta islets), the pituitary gland, and the central nervous system (CNS). Provided by the invention are isolated PanCAM related polynucleotides and polypeptides, vectors, and host cells comprising any of the above, antibodies directed to PanCAM, cells which produce such antibodies, and related diagnostic and therapeutic methods.Type: ApplicationFiled: June 24, 2002Publication date: August 7, 2003Applicant: Biogen, Inc.Inventors: Chao Sun, John P. Carulli, Alexander V. Lukashin, Daniel R. Kilburn
-
Patent number: 6602503Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.Type: GrantFiled: May 31, 1995Date of Patent: August 5, 2003Assignee: Biogen, Inc.Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
-
Publication number: 20030138884Abstract: APRIL, a novel members of the tumor necrosis factor family (TNF), modified APRILs, and pharmaceutical compositions comprising them.Type: ApplicationFiled: May 1, 2002Publication date: July 24, 2003Applicant: Biogen, Inc.Inventor: Jurg Tschopp
-
Patent number: 6596687Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.Type: GrantFiled: January 13, 2000Date of Patent: July 22, 2003Assignee: Biogen, Inc.Inventors: Ko-Chung Lin, Steven P. Adams, Alfredo C. Castro, Craig N. Zimmerman, Julio Hernan Cuervo, Wen-Cherng Lee, Charles E. Hammond, Mary Beth Carter, Ronald G. Almquist
-
Publication number: 20030095969Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissus in the gut.Type: ApplicationFiled: September 23, 2002Publication date: May 22, 2003Applicant: Biogen,Inc., a Massachusetts corporationInventors: Roy R. Lobb, Linda C. Burkly
-
Publication number: 20030083267Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.Type: ApplicationFiled: August 22, 2001Publication date: May 1, 2003Applicant: Biogen, Inc., a Massachusetts corporationInventors: Steven P. Adams, Ko-Chung Lin, Wen-Cherng Lee, Alfredo C. Castro, Craig N. Zimmerman, Charles E. Hammond, Yu-Sheng Liao
-
Patent number: 6552216Abstract: Pharmacophore models of VLA-4 inhibitors, methods of identifying novel inhibitors and novel inhibitors identified by these methods.Type: GrantFiled: January 25, 1999Date of Patent: April 22, 2003Assignee: Biogen, Inc.Inventors: Juswinder Singh, Zhongli Zheng, Peter Sprague, Herman Van Vlijmen, Alfredo Castro, Steven P. Adams
-
Publication number: 20030072754Abstract: Methods and compositions for inhibiting rejection of insulin-producing tissue in a graft recipient, as well as methods and compositions for prolonging graft survival or function; for reversing graft rejection or restoring function of an impaired graft; and, for inducing immunological tolerance to grafted, insulin-producing tissue. The present methods and compositions are suitable for treatment or prophylaxis of defects in metabolic control of blood glucose homeostasis, including defects manifested as diabetes mellitus (DM).Type: ApplicationFiled: October 11, 2002Publication date: April 17, 2003Applicant: Biogen, Inc.Inventors: Norma S. Kenyon, Camillo Ricordi, David W. Thomas, Linda Burkly
-
Patent number: 6544520Abstract: Peptides and other molecules which inhibit the assembly of the hepatitis B virus, methods of treatment, and pharmaceutical compositions comprising them.Type: GrantFiled: April 29, 1999Date of Patent: April 8, 2003Assignee: Biogen, Inc.Inventors: Kenneth Murray, Michael Richard Dyson
-
Patent number: 6495525Abstract: OMePUPA-V, (R)-N-[[4-[[(2-methylphenylamino)carbonyl]amino]phenyl]acetyl]-L-prolyl-3-methyl)-&bgr;-Alanine, a cell adhesion inhibitor, pharmaceutical compositions, and methods of treatment of cell-adhesion mediated pathologies.Type: GrantFiled: November 28, 2000Date of Patent: December 17, 2002Assignee: Biogen, Inc.Inventors: Wen-Cherng Lee, Alan Gill
-
Publication number: 20020172671Abstract: CAIP polypeptide, nucleic acids, ands uses thereof.Type: ApplicationFiled: May 13, 2002Publication date: November 21, 2002Applicant: Biogen, Inc., a Massachusetts corporationInventor: Yen-Ming Hsu
-
Patent number: 6482409Abstract: A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of a VCAM-1/IgG fusion protein.Type: GrantFiled: September 21, 1998Date of Patent: November 19, 2002Assignee: Biogen, Inc.Inventors: Roy R. Lobb, Linda C. Burkly